Part 2/7:
For people with diabetes, insulin is not a luxury—it’s a necessity. Yet, despite the minimal cost of production—ranging from $1.50 to $5 per vial—market prices reach up to $300 or more per vial. The reason? A highly concentrated supply chain dominated by just three pharmaceutical companies that own 90% of the global insulin market. These companies have consistently raised prices, often in lockstep, making it increasingly difficult for patients to access this essential medication.
Katie, like many others, shared her personal heartbreak after being unable to pay for her son’s insulin, highlighting how rising costs threaten lives. As prescription costs skyrocket, the disparity between production costs and retail prices exemplifies how systemic barriers prevent affordable healthcare access.